Drug Database
Back to search

United States· US:62542-101_4cdb19d3-49f4-c257-e063-6294a90aaabd

Carbinoxamine Maleate Extended-Release Oral Suspension

A carbinoxamine product containing carbinoxamine maleate, registered in United States by Neos Therapeutics, LP.

ATC R06AA08US label

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedCarbinoxamine Maleate Extended-Releas…ATCR06AA08REGISTER NO.US:62542-101_4cdb19d3…PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about carbinoxamine maleateAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
CARBINOXAMINE MALEATE
Manufacturer
Neos Therapeutics, LP
Country
United States (US)
ATC code
R06AA08
ATC class
Carbinoxamine
Defined daily dose
16 mg, O
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
September 27, 2026

Packs & prices · 2

  • ndc11
    62542-101-05
  • ndc11
    6254210105
    480 mL in 1 BOTTLE, PLASTIC (62542-101-05)

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

320 interactions on record for carbinoxamine.

Graded by severity as the source publishes them — 9 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check carbinoxamine against other medicinesHow interaction checks work

Carbinoxamine · interactions on record

320 records

  • 9 severe
  • 309 moderate
  • 2 minor

Most severe, free to view

  • Potassium chlorideA12BA01severe
  • Potassium citrateA12BA02severe
  • Potassium chlorideB05XA01severe
  • Sodium oxybateN01AX11severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same class

Other records under R06AA08

Carbinoxamine, as other registers publish it.

All carbinoxamine products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/9f8fde61-8c8e-47e6-a508-494528a8caae
GET /v1/drugs/9f8fde61-8c8e-47e6-a508-494528a8caae?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "ORAL",
  "source": "ndc",
  "strength": "4",
  "substance": "CARBINOXAMINE MALEATE",
  "productndc": "62542-101",
  "dosage_form": "SUSPENSION, EXTENDED RELEASE",
  "dea_schedule": null,
  "strength_unit": "mg/5mL",
  "application_number": "NDA022556",
  "marketing_category": "NDA AUTHORIZED GENERIC"
}
API referenceMCP serverPlans

See everything about carbinoxamine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console